Kathryn R. Bowles

2 months ago | cell.com | Alexander Fröhlich |Kathryn R. Bowles

SpotlightOnline nowOpen access1UK Dementia Research Institute, University of Edinburgh, Edinburgh EH16 4SB, UK2Centre for Discovery Brain Sciences, University of Edinburgh, Chancellor’s Building, Edinburgh EH16 4SB, UKPublication History:Published online February 10, 2025DOI: 10.1016/j.tins.2025.01.004Also available on ScienceDirectCopyright: © 2025 The Author(s). Published by Elsevier Ltd.

Nov 26, 2024 | cell.com | Kathryn R. Bowles |Chiara Pedicone |Derian A Pugh |Laura-Maria Oja |Brian Fulton-Howard |Sarah Weitzman | +5 more

CRISPR/Cas9 genome editingHuman iPSCs were edited using the pSpCas9(BB)-2A-GFP (PX458) construct backbone (Addgene #48138) described in Ran et al 201382. For WT correction of S305 mutation lines, specific guide RNAs (gRNAs) were designed against the mutant allele using the Zhang lab design tool (crispr.mit.edu), and guides with the highest quality scores and more than 3bp mismatches with other genomic loci were selected.

Jun 5, 2023 | biorxiv.org | Kathryn R. Bowles |Derian A Pugh |Chiara Pedicone |Laura-Maria Oja

New Results doi: https://doi.org/10.1101/2023.06.02.543224 AbstractDue to the importance of 4R tau in the pathogenicity of primary tauopathies, it has been challenging to model these diseases in iPSC-derived neurons, which express very low levels of 4R tau. To address this problem we have developed a panel of isogenic iPSC lines carrying the MAPT splice-site mutations S305S, S305I or S305N, derived from four different donors.